VivoSeq
Neurology

Spinal Cord Injuries

0

Pipeline Programs↗

14

Active Trials↗

3

Companies Involved↗

Spinal Cord Injuries is an early-stage landscape with 0 programs across 3 companies. The most active players are Eli Lilly, Milap Sandhu, Vertex Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

25/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 1M

Milap Sandhu

0 programs

PreclinicalVertex Pharmaceuticals logo

Vertex Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

22

clinical trials

Recruiting9 · 41%
Completed8 · 36%
Active, not recruiting3 · 14%
Enrolling by invitation1 · 5%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

22 trials

Development of a Novel Soluble Epoxide Hydrolase Inhibitor as a Strategy for Treating Neuropathic Pain in Patients With SCI
Recruiting·EEicOsis Human Health Inc.·Phase 1·NCT06438471·36 enrolled
Evaluation of Advanced Lower Extremity Neuroprostheses
Recruiting·CCase Western Reserve University·Preclinical·NCT00623389·10 enrolled
Can Increasing Motor Evoked Potential Size Improve Upper Extremity Motor Function in Individuals With Incomplete Spinal Cord Injury?
Recruiting·MMedical University of South Carolina·Preclinical·NCT05321017·5 enrolled
Critical Time Window for Rehabilitation After Incomplete Spinal Cord Injury: Early vs Late Locomotor Training
Recruiting·—·Preclinical·NCT06176833·108 enrolled
Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling
Recruiting·SSt George's, University of London·Preclinical·NCT04936620·222 enrolled
An Early Feasibility Study of Using the AccelBand, a Leg-worn Transcutaneous Neuromodulation (TNM) Device, for Neurogenic Bowel Dysfunction (NBD) in People With Spinal Cord Injury (SCI)
Recruiting·UUniversity of Michigan·Preclinical·NCT07171489·100 enrolled
The Effects of a Hybrid HIIT-FES Cycling Program on Individuals With Spinal Cord Injury to Improve Cardiovascular and Metabolic Health
Recruiting·William Carey University·Preclinical·NCT07648173·12 enrolled
Efficacy of Repetitive Transcranial Magnetic Stimulation Therapy in Neuropathic Pain Associated With Spinal Cord Injury; Randomized Controlled Trial
Recruiting·AAfyonkarahisar Health Sciences University·Preclinical·NCT06726954·63 enrolled
mHealth-based Just-In-Time Adaptive Intervention to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Recruiting·TTemple University·Phase 2·NCT05317832·196 enrolled
Evaluating the Effectiveness of the Collaborative Community Clinic for Persons With Spinal Cord Injury and Disease
Active, not recruiting·WWashington University School of Medicine·N/A·NCT04457206·200 enrolled
Dosing of Overground Robotic Gait Training With Functional Outcomes and Neuroplasticity After Spinal Cord Injury
Active, not recruiting·BBaylor Research Institute·Preclinical·NCT05218447·98 enrolled
Transcutaneous Spinal Direct Current Stimulation to Enhance Locomotor Rehabilitation After Spinal Cord Injury
Active, not recruiting·UUniversity of Florida·Preclinical·NCT05700942·30 enrolled
Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury: Short and Long-Term Effects
Not yet recruiting·KKessler Foundation·Preclinical·NCT07674511·10 enrolled
Combined Transcutaneous Spinal Stimulation + FES-Assisted Cough Training in Acute SCI
Enrolling by invitation·—·Preclinical·NCT07683780·60 enrolled
Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries
Completed·PPuerta de Hierro University Hospital·Phase 2·NCT02570932·10 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)